Xencor, Inc. (NASDAQ:XNCR) Receives $29.50 Consensus Price Target from Brokerages

Shares of Xencor, Inc. (NASDAQ:XNCR - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine analysts that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $29.50.

XNCR has been the topic of several analyst reports. Wedbush reiterated an "outperform" rating and issued a $31.00 target price on shares of Xencor in a research note on Wednesday, April 30th. StockNews.com downgraded Xencor from a "hold" rating to a "sell" rating in a research note on Friday, March 14th. Wells Fargo & Company decreased their price target on Xencor from $37.00 to $33.00 and set an "overweight" rating on the stock in a research note on Friday, February 28th. William Blair began coverage on Xencor in a research note on Monday, April 21st. They issued an "outperform" rating on the stock. Finally, Barclays decreased their price target on Xencor from $22.00 to $6.00 and set an "underweight" rating on the stock in a research note on Thursday, May 8th.

Insiders Place Their Bets

In other Xencor news, EVP Nancy Valente sold 4,616 shares of the business's stock in a transaction on Friday, May 2nd. The stock was sold at an average price of $11.03, for a total transaction of $50,914.48. Following the sale, the executive vice president now directly owns 49,169 shares in the company, valued at approximately $542,334.07. The trade was a 8.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 4.76% of the stock is owned by company insiders.

Institutional Trading of Xencor

A number of institutional investors have recently bought and sold shares of XNCR. Sterling Capital Management LLC raised its holdings in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,040 shares during the last quarter. GF Fund Management CO. LTD. acquired a new position in shares of Xencor in the fourth quarter worth $34,000. State of Wyoming acquired a new position in shares of Xencor in the first quarter worth $34,000. CWM LLC raised its holdings in shares of Xencor by 195.5% in the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 2,231 shares during the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 508 shares during the last quarter.

Xencor Stock Performance

XNCR traded down $0.14 during trading on Wednesday, hitting $8.06. 728,455 shares of the stock were exchanged, compared to its average volume of 646,270. The firm has a market capitalization of $573.49 million, a P/E ratio of -2.52 and a beta of 0.99. Xencor has a 1-year low of $7.16 and a 1-year high of $27.24. The stock has a fifty day moving average price of $10.18 and a two-hundred day moving average price of $17.21. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The company had revenue of $32.73 million during the quarter, compared to analysts' expectations of $23.44 million. During the same quarter last year, the business posted ($1.11) earnings per share. The company's revenue for the quarter was up 104.6% compared to the same quarter last year. As a group, sell-side analysts predict that Xencor will post -3.68 earnings per share for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.